速递 |“减脂不减肌”，柯君医药公布新一代减重药物CG-0416临床前突破性数据

Core Viewpoint - The article highlights the breakthrough clinical data of CG-0416, a novel oral weight loss drug developed by Kejun Pharmaceutical, which targets liver metabolism and offers a new option for obesity treatment globally [5][6]. Group 1: Drug Mechanism and Advantages - CG-0416 is developed based on the thyroid hormone receptor beta (THR-β) target, demonstrating high liver targeting and promoting fat burning and energy expenditure, leading to effective reduction of liver fat accumulation [6][8]. - The drug achieves weight loss without appetite suppression, resulting in a high-quality weight loss effect characterized as "fat loss without muscle loss" [6][8]. - Clinical data shows that approximately 95% of weight loss from CG-0416 comes from fat reduction, contrasting with GLP-1 drugs where about one-third of weight loss is from muscle loss [8]. Group 2: Safety and Side Effects - CG-0416 is expected to significantly reduce gastrointestinal side effects such as nausea and vomiting, thereby improving patient compliance [8]. - The drug also lowers lipid levels in blood and liver, improving triglyceride and blood sugar tolerance, contributing to overall metabolic health benefits [8]. Group 3: Combination Therapy - Research indicates that combining CG-0416 with various GLP-1 receptor agonists, such as semaglutide, shows a strong synergistic effect, enhancing weight loss from 24% to 40% in certain models [9]. - The combination therapy alleviates muscle loss associated with standalone GLP-1 drug use, increasing the proportion of muscle post-weight loss [9]. - This dual pathway approach of central appetite regulation (GLP-1) and peripheral liver metabolism activation (CG-0416) offers a new solution for severely obese patients needing significant weight loss and metabolic remodeling [9].